AI Breakthrough: New Drug Shows Promise in Treating Incurable Lung Disease

A drug developed by artificial intelligence has demonstrated signs of effectiveness in treating a severe lung condition, according to biopharmaceutical company Insilico Medicine, as reported by Bloomberg.

This marks the first instance where a «generated» drug has successfully completed an intermediate stage of clinical trials, according to the startup.

The medication, known as rentosertib, was shown to improve lung function in a small group of patients diagnosed with idiopathic pulmonary fibrosis, a condition where scarring of the lungs makes breathing difficult. Biomarker analysis indicated that the drug operates exactly as envisioned by the AI, reducing a protein believed to be linked to the disease.

«This is one of the most remarkable outcomes ever achieved in the treatment of lung diseases,» commented Insilico’s CEO, Alex Zhavoronkov.

Insilico Medicine is planning more extensive trials to verify the effects of rentosertib. The company aims to gather feedback from regulators and potential pharmaceutical partners.

The findings will serve as a foundational base for more than 30 programs at Insilico and will contribute to the enhancement of the AI model, noted Zhavoronkov.

The study lasted for 12 weeks and involved 71 patients, all of whom were from China. Some patients experienced deterioration in their condition, while others encountered liver issues.

Zhavoronkov believes the side effects can be managed, and he considers the drug to be “sufficiently safe.”

Additionally, it’s worth noting that in March, Google introduced open AI models for the discovery of new medications.